Zai Lab Limited (NASDAQ:ZLAB) Holdings Trimmed by Mirae
1 day ago · Mirae Asset Global Investments Co. Ltd.'s holdings in Zai Lab were worth $107,000 as of its most recent filing with the Securities and Exchange Commission. Several other hedge funds have also recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its holdings in shares of Zai Lab by 51.2% during the first quarter.
Zai Lab Limited (ZLAB) Stock Price, News, Quote & History
Find the latest Zai Lab Limited (ZLAB) stock quote, history, news and other vital information to help you with your stock trading and investing.
Home - Zai Lab
News. Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China. October 29, 2024. ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer.
Zai Lab Limited (ZLAB) Latest Stock News & Headlines - Yahoo …
Get the latest Zai Lab Limited (ZLAB) stock news and headlines to help you in your trading and investing decisions.
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for …
May 13, 2024 · The approval is based on the pivotal TRIDENT-1 trial, in which AUGTYRO achieved a high response rate and durable responses, including robust intracranial responses.
Zai Lab Announces Strategic Partnership and Global ... - Zai Lab …
Apr 27, 2023 · SHANGHAI, China and CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics (MediLink).
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial ...
Oct 29, 2024 · The Zai Lab Phase 3 multi-center, randomized, placebo-controlled trial (ZL-2701-001) evaluated the efficacy and safety of KarXT in 202 acutely psychotic hospitalized adult patients with ...
Zai Lab, A Top 6% Stock, Rockets On 'Impressive' Lung Cancer …
Oct 24, 2024 · Shares of Zai Lab (ZLAB) rocketed to a 16-month high Thursday after the Chinese biotech posted "impressive" results for its lung cancer treatment. The Cell Therapy Market Is Expected To Grow...
BMS partner Zai Lab eyes China filing for KarXT after trial win
Oct 29, 2024 · Patients on the drug, also known as KarXT, achieved a 16.9-point reduction on the scale, Zai Lab said. The improvement for those on placebo came to 7.7 points. Zai Lab’s phase 3 trial looked at ...
Investor Overview – Zai Lab Limited
Oct 29, 2024 · Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world.
- Some results have been removed